MAYZENT Drug Patent Profile

When do Mayzent patents expire, and what generic alternatives are available?

Mayzent is a drug marketed by Novartis and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MAYZENT is siponimod. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the siponimod profile page.

DrugPatentWatch^® Generic Entry Outlook for Mayzent

Mayzent was eligible for patent challenges on March 26, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2032. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (siponimod), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for MAYZENT

US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	3
Drug Prices:	Drug price information for MAYZENT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAYZENT
What excipients (inactive ingredients) are in MAYZENT?	MAYZENT excipients list
DailyMed Link:	MAYZENT at DailyMed

See drug prices for MAYZENT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MAYZENT

NDA:

209884

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MAYZENT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Robert Zivadinov, MD, PhD	Phase 4
Novartis Pharmaceuticals	Phase 4
Novartis Pharmaceuticals	Phase 3

See all MAYZENT clinical trials

Pharmacology for MAYZENT

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Paragraph IV (Patent) Challenges for MAYZENT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAYZENT	Tablets	siponimod	0.25 mg, 1 mg and 2 mg	209884	5	2023-03-27

US Patents and Regulatory Information for MAYZENT

MAYZENT is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-001	Mar 26, 2019		RX	Yes	No
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-003	Aug 24, 2021		RX	Yes	No
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-001	Mar 26, 2019		RX	Yes	No			Y	Y
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-002	Mar 26, 2019		RX	Yes	Yes

International Patents for MAYZENT

When does loss-of-exclusivity occur for MAYZENT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MAYZENT around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2973540	TRAITEMENT DE MALADIE AUTO-IMMUNE CHEZ UN PATIENT RECEVANT EN OUTRE UN BETABLOQUANT (TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER)
World Intellectual Property Organization (WIPO)	2016135644
Argentina	084801
Argentina	124662

Supplementary Protection Certificates for MAYZENT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379069	301046	Netherlands		PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: EU/1/19/1414 20200115
2379069	CA 2020 00026	Denmark		PRODUCT NAME: SIPONIMOD; REG. NO/DATE: EU/1/19/1414 20200115
2379069	122020000025	Germany		PRODUCT NAME: SIPONIMOD; REGISTRATION NO/DATE: EU/1/19/1414 20200113
2379069	LUC00160	Luxembourg		PRODUCT NAME: SIPONIMOD; AUTHORISATION NUMBER AND DATE: EU/1/19/1414 20200115

Mayzent Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: August 19, 2026

Mayzent, the brand name for siponimod, is a Novartis oral sphingosine-1-phosphate receptor modulator approved for adults with active secondary progressive multiple sclerosis (SPMS). Its commercial position depends on a narrow but clinically important indication, a first-mover advantage in active SPMS, and continued differentiation from broader multiple sclerosis therapies. Novartis reported Mayzent sales growth after launch, but the product faces competitive pressure from Ocrevus, Kesimpta, Briumvi, Ponvory, Zeposia, generic fingolimod, and other disease-modifying therapies.

The principal commercial issue is the size and treatment rate of the active-SPMS population. The principal legal issue is the remaining U.S. patent estate after Mayzent’s five-year new chemical entity exclusivity ended in March 2024. No biosimilar pathway applies because siponimod is a synthetic small molecule.

What is Mayzent and how does siponimod work?

Mayzent contains siponimod, an oral selective modulator of sphingosine-1-phosphate receptor subtypes 1 and 5. The drug reduces lymphocyte migration from lymphoid tissue and has central nervous system activity relevant to multiple sclerosis. The FDA approved Mayzent on March 26, 2019, for adults with active SPMS, defined by relapses or imaging evidence of inflammatory disease activity (FDA, 2024a).

Unlike treatments approved for relapsing forms of multiple sclerosis, Mayzent’s U.S. label specifically addresses active SPMS. That positioning gives Novartis access to a clinically differentiated population, but the label does not cover all nonactive SPMS patients.

What clinical evidence supports Mayzent?

The approval was based primarily on the EXPAND study, a randomized Phase 3 trial in patients with SPMS. Siponimod reduced the risk of three-month confirmed disability progression compared with placebo in the overall study population. The treatment effect was more pronounced in patients with active SPMS, which became the basis for the U.S. indication (Kappos et al., 2018).

Mayzent requires CYP2C9 genotype testing before initiation. Patients with certain CYP2C9 genotypes are unsuitable for treatment because of altered siponimod exposure. The drug also requires dose titration and has contraindications and warnings involving cardiac conduction, macular edema, liver function, infections, and fetal risk (FDA, 2024a).

What is the FDA regulatory status of Mayzent?

Mayzent is FDA-approved and commercially marketed in the United States. Its regulatory milestones are:

Milestone	Date
FDA approval	March 26, 2019
U.S. indication	Adults with active SPMS
Active ingredient	Siponimod
Dosage form	Oral tablets
NCE exclusivity	Approximately March 2019 to March 2024
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated New Drug Application, or ANDA

The approval did not create orphan-drug exclusivity because multiple sclerosis is not an orphan disease in the United States. Mayzent’s initial regulatory protection therefore came principally from its NCE status, listed patents, and any applicable pediatric or regulatory extensions.

When does Mayzent lose exclusivity?

Mayzent’s five-year NCE exclusivity expired in March 2024, assuming no regulatory extension altered the date. NCE exclusivity prevents FDA approval of an ANDA or 505(b)(2) application that relies on the drug’s reference product during the exclusivity period. It does not prevent independent approval of a full new drug application.

Patent protection can extend beyond NCE exclusivity. The relevant commercial question is the earliest date on which a generic applicant can both obtain FDA approval and launch without violating enforceable patent claims or a settlement agreement.

What patents protect Mayzent?

Mayzent’s protection is based on a combination of compound, pharmaceutical composition, dosing, and method-of-use claims. The exact Orange Book listing and expiration analysis should be performed against the current FDA database because patent listings and expiration dates can change through corrections, terminal disclaimers, pediatric extensions, or litigation outcomes.

The principal patent categories are:

Patent category	Commercial purpose	Generic risk
Siponimod compound patents	Protect the active pharmaceutical ingredient and related chemical forms	Highest barrier if valid and unexpired
Pharmaceutical composition patents	Protect tablet formulations and excipient combinations	Potentially avoidable through formulation design
Dosing and titration patents	Protect treatment initiation or dose-adjustment regimens	May be avoided by label carving or alternative instructions
Method-of-use patents	Protect treatment of SPMS or particular patient populations	Vulnerable to skinny-label strategies
Manufacturing and process patents	Protect synthesis, purification, or solid-state forms	Can delay development but may not block all generic entry

Publicly available patent records associate siponimod protection with Novartis entities and related research organizations. The most important diligence source for U.S. launch timing is the current FDA Orange Book listing, followed by USPTO prosecution records and any Paragraph IV litigation docket.

What is the Orange Book status of Mayzent?

The Orange Book determines which patents Novartis has listed against the reference product and identifies the regulatory exclusivity framework relevant to ANDA applicants. For Mayzent, the key distinction is between:

1. Patents that claim siponimod itself.
2. Patents that claim formulations or dosage forms.
3. Patents that claim methods of treating multiple sclerosis or SPMS.
4. Patents that may be challenged through a Paragraph IV certification.

An ANDA applicant can certify that a listed patent has expired, will expire before commercial marketing, is not infringed, or is invalid. A Paragraph IV notice gives the brand company 45 days to file an infringement action. A timely lawsuit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and court decisions.

No broad public record through mid-2024 established a major Mayzent Paragraph IV litigation campaign comparable to the litigation surrounding larger multiple sclerosis brands such as Gilenya. That absence does not eliminate generic risk. Generic applicants may remain in confidential development, pursue non-infringement positions, or wait for patent expiration without triggering a public dispute.

What Mayzent patent litigation affects generic entry?

The main litigation risks concern whether generic applicants challenge:

• The validity of the core compound patent.
• The scope of claims covering siponimod polymorphs or salts.
• Formulation claims covering the commercial tablet.
• Method-of-use claims covering active SPMS.
• Any patent listed after the original approval date.

A generic applicant may seek approval with a label that omits patented indications or dosing instructions. This strategy, known as a skinny label, is more viable when the core compound patent has expired and the remaining patents cover only methods of use.

For Novartis, formulation and method patents are commercially useful because they can extend protection beyond the active-ingredient patent. Their practical strength is lower if a generic can demonstrate bioequivalence using a different formulation or market a label that omits the protected use.

How strong is the Mayzent patent estate?

Mayzent’s patent estate is strategically meaningful but less durable than estates built around multiple high-value formulation platforms, long-acting delivery systems, or biologic manufacturing controls.

Strengths

• A differentiated active-SPMS indication creates method-of-use value.
• Siponimod’s pharmacogenomic dosing requirements may complicate development and labeling.
• Tablet formulation claims can create a secondary barrier after compound protection expires.
• The commercial product has a defined titration schedule and patient-selection process.

Weaknesses

• Mayzent is a small molecule, so generic substitution is technically feasible.
• NCE exclusivity has expired.
• Formulation claims may be designed around.
• Method-of-use claims may be avoided through a narrower label.
• The product competes with therapies that are approved across broader multiple sclerosis populations.

The estate is strongest when the core active-ingredient patent remains enforceable. It becomes materially weaker when only formulation, dosing, or method-of-use claims remain.

How has Mayzent revenue developed?

Mayzent revenue grew from a low post-launch base as neurologists adopted siponimod for active SPMS and Novartis expanded payer and clinical awareness. Novartis reported the following approximate annual sales trajectory in its financial reporting:

Year	Mayzent sales
2019	Initial launch year
2020	Approximately $272 million
2021	Approximately $480 million
2022	Approximately $600 million
2023	Approximately $780 million

Sources report results in U.S. dollars and may present growth on a constant-currency basis. Novartis financial statements should control for audited annual totals and currency presentation (Novartis, 2021, 2022, 2023).

The pattern indicates a product that reached meaningful scale but remained below the multibillion-dollar revenue level of leading broad-population multiple sclerosis therapies. The revenue base reflects the narrower active-SPMS label, competition from high-efficacy agents, and the limited size of the addressable population.

What drives Mayzent revenue?

Mayzent sales depend on:

• The number of patients diagnosed with active SPMS.
• Neurologist willingness to use disease-modifying treatment after transition from relapsing disease.
• Payer coverage and prior-authorization criteria.
• Acceptance of CYP2C9 testing.
• Persistence and adherence with oral treatment.
• Switching from other disease-modifying therapies.
• The extent to which physicians use broader-label competitors before or after SPMS progression.

The product has a commercial advantage in oral administration and an indication directly associated with active SPMS. It has a disadvantage against therapies with stronger familiarity, broader labels, larger sales forces, or established treatment pathways.

How does Mayzent compare with competing multiple sclerosis drugs?

Drug	Company	Route	Key competitive position
Mayzent	Novartis	Oral	Approved for active SPMS; CYP2C9-guided dosing
Ocrevus	Roche/Genentech	Intravenous	Broad use in relapsing MS and primary progressive MS
Kesimpta	Novartis	Subcutaneous	High-growth self-administered anti-CD20 therapy
Briumvi	TG Therapeutics	Intravenous	Anti-CD20 competitor for relapsing MS
Ponvory	Johnson & Johnson	Oral	S1P modulator for relapsing forms of MS
Zeposia	Bristol Myers Squibb	Oral	S1P modulator for relapsing MS
Gilenya	Novartis and generics	Oral	Established S1P product with generic competition
Mavenclad	Merck KGaA	Oral	Short-course immune reconstitution approach

Mayzent competes most directly with high-efficacy therapies used in patients with active disease. It also competes indirectly with products that prevent or delay progression before patients reach active SPMS.

Kesimpta creates a particularly important internal Novartis comparison. Kesimpta has a broader relapsing-MS opportunity and has been one of Novartis’s fastest-growing products. Internal portfolio decisions may favor Kesimpta in earlier-line or broader populations, while Mayzent remains focused on active SPMS.

What generic entry risks exist for Mayzent?

Generic entry risk is low during any period in which a valid, enforceable compound patent blocks approval or launch. Risk rises in stages:

Near-term risk

After NCE exclusivity expiration, ANDA applicants can submit applications and challenge listed patents. This creates regulatory and litigation risk even before approval.

Mid-term risk

If compound protection expires or is invalidated, generic applicants may target the tablet formulation and seek approval with a label excluding patented methods of use.

Launch risk

The first successful Paragraph IV applicant may qualify for 180 days of generic exclusivity, depending on the statutory and litigation circumstances. A settlement could authorize an agreed launch date earlier than the final patent expiration date.

Price erosion

A first generic entrant can reduce net price materially, although erosion may be slower than in high-volume primary-care products because Mayzent is a specialty medicine with specialist prescribing, diagnostic requirements, and payer controls.

What manufacturing and intellectual-property barriers affect Mayzent?

Siponimod is a synthetic small molecule, so its manufacturing barrier is lower than the barrier for a monoclonal antibody. Generic developers must establish:

• Chemical synthesis and impurity control.
• Solid-state or polymorph consistency.
• Tablet dissolution and stability.
• Bioequivalence across the titration regimen.
• Reliable supply of the active pharmaceutical ingredient.
• Appropriate labeling for CYP2C9 testing and contraindications.

Process patents may raise development costs but generally do not block entry if a non-infringing manufacturing route is available. The more durable barriers are likely to be active-ingredient, formulation, and regulatory patents rather than manufacturing complexity alone.

Has Novartis licensed Mayzent rights?

Mayzent was developed and commercialized by Novartis. No widely disclosed third-party licensing transaction has been identified as a central element of the product’s commercial rights structure through 2024. Any regional co-promotion, manufacturing, or distribution arrangements would need to be assessed separately from ownership of the core siponimod intellectual property.

What is the geographic coverage of Mayzent?

Mayzent has been commercialized in the United States and other major pharmaceutical markets, subject to local regulatory approvals and reimbursement decisions. Patent coverage differs by jurisdiction. U.S. timing is governed by FDA Orange Book listings, U.S. patent term rules, and Paragraph IV litigation. European timing depends on European Patent Convention designations, national validation, supplementary protection certificates, and national litigation.

A U.S. generic launch does not automatically establish freedom to launch in Europe, Japan, Canada, or other markets. Geographic risk must be analyzed on a country-by-country basis.

What is the outlook for Mayzent’s financial trajectory?

Mayzent’s revenue outlook is likely to follow three phases:

1. Continued specialty-product growth while Novartis expands active-SPMS use and protects share.
2. Slower growth as the eligible population matures and competitors capture patients earlier in the disease course.
3. Revenue compression after generic entry, with the magnitude determined by patent settlements, launch sequencing, payer substitution, and the number of entrants.

The product’s revenue ceiling is constrained by its indication. Novartis can improve the trajectory through diagnosis of active SPMS, treatment persistence, evidence generation, and payer access. It cannot fully offset the structural limitation that Ocrevus, Kesimpta, Briumvi, Zeposia, and other agents address broader or overlapping populations.

Revenue exposure is material for Novartis but modest relative to its largest franchises. Mayzent is strategically relevant as an active-SPMS product and as part of Novartis’s multiple sclerosis portfolio, while Kesimpta has the stronger long-term growth profile because of its broader addressable market.

Key Takeaways

• Mayzent is an FDA-approved oral treatment for adults with active SPMS.
• Its five-year NCE exclusivity ended in March 2024.
• The remaining commercial barrier depends on listed patents covering siponimod, formulations, dosing, and methods of use.
• Siponimod is a small molecule, so biosimilar risk does not apply and generic development is technically feasible.
• The product generated approximately $780 million in 2023 sales based on Novartis reporting.
• Its market is constrained by the size of the active-SPMS population and competition from broader multiple sclerosis therapies.
• The most important launch variables are core patent expiry, Paragraph IV filings, settlement terms, and the number of generic entrants.
• Mayzent’s patent estate is strongest when compound protection remains enforceable and weaker when only formulation or method-of-use claims remain.

FAQs About Mayzent Patents, Sales, and Competition

Is Mayzent a biologic or a small-molecule drug?

Mayzent is a synthetic small-molecule drug containing siponimod. Generic companies can pursue an ANDA rather than a biosimilar application.

Does Mayzent have orphan-drug exclusivity?

No. Mayzent’s U.S. approval for active SPMS did not provide orphan-drug exclusivity because multiple sclerosis is not an orphan indication under the applicable FDA framework.

Does Mayzent require genetic testing?

Yes. CYP2C9 genotype testing is required before treatment to identify patients who may have excessive siponimod exposure or should not receive the drug.

Which Novartis drug has greater growth potential, Mayzent or Kesimpta?

Kesimpta has the broader growth opportunity because it addresses relapsing multiple sclerosis across a larger patient population. Mayzent has a more specialized position in active SPMS.

Can a generic launch after Mayzent’s NCE exclusivity expires?

Not necessarily. NCE exclusivity expiration permits ANDA review, but a generic may still be blocked by unexpired patents, a 30-month litigation stay, a court injunction, or a settlement restricting launch.

References

Food and Drug Administration. (2024a). Mayzent (siponimod) prescribing information. U.S. Department of Health and Human Services.

Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherzinger, A., Wolf, C., Wallström, E., and the EXPAND Clinical Investigators. (2018). Siponimod versus placebo in secondary progressive multiple sclerosis. The Lancet, 391(10127), 1263-1273.

Novartis AG. (2021). Annual report 2021. Novartis.

Novartis AG. (2022). Annual report 2022. Novartis.

Novartis AG. (2023). Annual report 2023. Novartis.

DrugChatter Q&A for MAYZENT

Mayzent generic name?
Mayzent availability in pharmacies?